Close

Tobira Therapeutics (TBRA) Begins Phase 1 Combination Study of Cenicriviroc and Evogliptin

September 12, 2016 8:06 AM EDT Send to a Friend
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login